Curis, Genentech and NCI enter partnership for new oncology candidate
The USA's Curis, Genentech and the National Cancer Institute's Division of Cancer Treatment and Diagnosis are to enter into a cooperative R&D agreement for GDC-0449, an orally-administered, Hedge- hog Pathway Inhibitor, in a number of cancer indications. A DCTD-sponsored Phase I trial is expected to be initiated to evaluate dose and safety of the agent in pediatric patients with medulloblastoma, a rare but highly-malignant brain tumor that occurs most often in children. In addition, the NCI plans to sponsor additional trials in patients with small cell lung and pancreatic cancers, among others.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze